A Dose Escalation Phase II Study of Sunitinib Plus Erlotinib in Advanced Renal Carcinoma.
Phase of Trial: Phase II
Latest Information Update: 05 May 2017
At a glance
- Drugs Erlotinib (Primary) ; Sunitinib
- Indications Renal cancer
- Focus Adverse reactions; Therapeutic Use
- 09 Jun 2011 Planned End Date changed from 1 May 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 19 Jan 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 19 Jan 2010 Planned end date changed from 1 Nov 2008 to 1 May 2010 as reported by ClinicalTrials.gov.